Abstract
We investigate the impact of vaccination and asymptomatic testing uptake on SARS-CoV-2 transmission in a university student population using a stochastic compartmental model. We find that the magnitude and timing of outbreaks is highly variable under different vaccine uptake levels. With low level interventions (no asymptomatic testing, 30% vaccinated), 53-71% of students become infected during the first term; with high interventions (90% using asymptomatic testing, 90% vaccinated) cumulative incidence is 7-9%, with around 80% of these cases estimated to be asymptomatic. Asymptomatic testing is most useful when vaccine uptake is low: when 30% of students are vaccinated, 90% uptake of asymptomatic testing leads to almost half the case numbers. Under high levels of vaccine uptake (70-90%), case numbers in the student population are largely driven by community importation. Our findings suggest that vaccination is critical for controlling SARS-CoV-2 transmission in university settings with asymptomatic testing being a useful supporting measure.
Competing Interest Statement
JGW has received research funding from Gilead Sciences unrelated to this research. HC is a principal investigator on a grant funded by GlaxoSmithKline unrelated to this research. All other authors declare no competing interests.
Funding Statement
HC and EBP would like to acknowledge support from the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation at the University of Bristol. HC is additionally funded through an NIHR Career Development Fellowship [CDF-2018-11-ST2-015]. The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care, or UKHSA. CR is a member of the MRC Integrative Epidemiology Unit and receives support from the MRC (MC_UU_00011/5) and the University of Bristol. ATh is supported by the Wellcome Trust (217509/Z/19/Z) and UKRI through the JUNIPER consortium MR/V038613/1 and CoMMinS study MR/V028545/1. EBP, EN, AB and LD are supported by UKRI through the JUNIPER consortium (Grant Number MR/V038613/1). LD and EBP are further supported by MRC (Grant Number MC/PC/19067). LD acknowledges funding from EPSRC (EP/V051555/1 and The Alan Turing Institute, Grant EP/N510129/1). DE acknowledges funding from EPSRC (EP/W000032/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Faculty of Health Sciences Ethics Committee at the University of Bristol reviewed the study documentation and acknowledged that good ethical principles were adhered to and that the data analyzed can be used for research purposes and that the data collected can be used for publication. The study complied with the University of Bristol data protection policy for research studies (http://www.bristol.ac.uk/media-library/sites/secretary/documents/information-governance/data-protection-policy.pdf).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
4
Blogs/Media
Author Videos